International Journal of Hematology-Oncology and Stem Cell Research最新文献

筛选
英文 中文
Adrenal Insufficiency in Patients with Beta-Thalassemia Major in the Southeast of Iran. 伊朗东南部乙型地中海贫血患者肾上腺功能不全。
International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2022-07-01 DOI: 10.18502/ijhoscr.v16i3.10140
Ghasem Miri-Aliabad, Maryam Nakhaie Moghadam, Majid Naderi, Mahdie Saravani, Ramin Saravani, Saman Sargazi, Milad Shirvaliloo
{"title":"Adrenal Insufficiency in Patients with Beta-Thalassemia Major in the Southeast of Iran.","authors":"Ghasem Miri-Aliabad, Maryam Nakhaie Moghadam, Majid Naderi, Mahdie Saravani, Ramin Saravani, Saman Sargazi, Milad Shirvaliloo","doi":"10.18502/ijhoscr.v16i3.10140","DOIUrl":"https://doi.org/10.18502/ijhoscr.v16i3.10140","url":null,"abstract":"The Article Abstract is not available.","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"16 3","pages":"174-176"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/a2/IJHOSCR-16-174.PMC9831871.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10671890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric Medulloblastoma: Prognostic Value of Preoperative Blood Cell Ratios. 小儿髓母细胞瘤:术前血细胞比例的预后价值。
International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2022-07-01 DOI: 10.18502/ijhoscr.v16i3.10135
Ehsan Alimohammadi, Seyed Reza Bagheri, Atefeh Arast, Homa Hadidi, Roya Safari-Faramani
{"title":"Pediatric Medulloblastoma: Prognostic Value of Preoperative Blood Cell Ratios.","authors":"Ehsan Alimohammadi,&nbsp;Seyed Reza Bagheri,&nbsp;Atefeh Arast,&nbsp;Homa Hadidi,&nbsp;Roya Safari-Faramani","doi":"10.18502/ijhoscr.v16i3.10135","DOIUrl":"https://doi.org/10.18502/ijhoscr.v16i3.10135","url":null,"abstract":"<p><p><b>Background:</b> The prognostic significance of preoperative neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), and platelet to lymphocyte ratio (PLR) have been demonstrated in various tumors. This study aimed to evaluate the prognostic role of these ratios in pediatric medulloblastoma. <b>Materials and Methods:</b> Forty-three pediatric patients with medulloblastoma were evaluated, retrospectively. Clinical, radiological, and laboratory data were extracted from the electronic medical records of the patients. Univariate and multivariate Cox proportional hazard models were used to evaluate the impact of suggested variables, including NLR, LMR, and PLR on progression-free survival (PFS) and overall survival (OS). Kaplan-Meier curves were plotted for the assessment of PFS and OS. The Log-rank test was used to assess differences between the PFS and OS in the related categories.  <b>Results:</b> There were 27 males (62.8%) and 16 females (37.2%) with a mean age of 7.4 ±3.3 years. The median OS and PFS were 62.8 ±17.2 and 43.3 ±15.6 months, respectively. The multivariate Cox model showed the clinical risk group, NLR, and LMR as independent predictors of the PFS and the OS (p<0.05). The Log-rank test revealed that OS and PFS were higher in patients with NLR <4 and those with LMR ≥ 3.48 (p <0.05). There were no differences between patients with PLR>200 and PLR< 200 based on OS and PFS. <b>Conclusion:</b> Our results suggest an elevated preoperative NLR and a lowered preoperative LMR as simple predictors of survival in pediatric medulloblastoma. These cost-effective and easily available ratios, along with previously established variables, could be valuable to predict survival in pediatrics with medulloblastoma.</p>","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"16 3","pages":"131-139"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/5f/IJHOSCR-16-131.PMC9831869.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9172647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapidly Progressing Plasma Cell Leukemia with Underlying Plasmablastic Morphology: A Rare Case Report of a 25-Year Old Male 快速进展浆细胞白血病伴潜在浆母细胞形态:一例罕见的25岁男性病例报告
International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2022-07-01 DOI: 10.18502/ijhoscr.v16i3.10142
S. Saldanha, S. Goyal, L. Dasappa, L. Jacob, M. Babu, K. Lokesh, A. Rudresha, L. Rajeev, D. Madhumathi
{"title":"Rapidly Progressing Plasma Cell Leukemia with Underlying Plasmablastic Morphology: A Rare Case Report of a 25-Year Old Male","authors":"S. Saldanha, S. Goyal, L. Dasappa, L. Jacob, M. Babu, K. Lokesh, A. Rudresha, L. Rajeev, D. Madhumathi","doi":"10.18502/ijhoscr.v16i3.10142","DOIUrl":"https://doi.org/10.18502/ijhoscr.v16i3.10142","url":null,"abstract":"Multiple myeloma constitutes a wide spectrum of diseases, ranging from slow-growing monoclonal gammopathy of undetermined significance to rapidly progressing plasma cell leukemia. It is a very rarely diagnosed hematological malignancy in those less than 30 years of age. A 25-year-old male presented with complaints of fatigue and low-grade fever. On investigation, he was found to have bicytopeina and features of tumor lysis syndrome. Initially, this was thought to be indicative of acute leukemia. However, upon further analysis with bone marrow biopsy, serum protein electrophoresis, and immunofixation, it was determined that the patient had an IgG myeloma with plasmablastic morphology. It rapidly progressed and the peripheral smear started showing clusters of plasma cells suggesting a picture of plasma cell leukemia. The patient succumbed to this aggressive disease despite treatment. This case illustrates that myeloma should also be included in the differential diagnosis for young patients, especially the rare plasmablastic variant, which can be misdiagnosed as acute leukemia. The aggressive morphology also tends to show rapid progression to plasma cell leukemia, which has a poor prognosis.","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"35 1","pages":"184 - 188"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84646937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anticancer Effects of ZnO/CNT@Fe3O4 in AML-Derived KG1 Cells: Shedding Light on Promising Potential of Metal Nanoparticles in Acute Leukemia. ZnO/CNT@Fe3O4在aml来源的KG1细胞中的抗癌作用:揭示金属纳米颗粒在急性白血病中的前景
International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2022-07-01 DOI: 10.18502/ijhoscr.v16i3.10136
Amir-Mohammad Yousefi, Atieh Pourbagheri-Sigaroodi, Zahra Fakhroueian, Sina Salari, Kosar Fateh, Majid Momeny, Davood Bashash
{"title":"Anticancer Effects of ZnO/CNT@Fe<sub>3</sub>O<sub>4</sub> in AML-Derived KG1 Cells: Shedding Light on Promising Potential of Metal Nanoparticles in Acute Leukemia.","authors":"Amir-Mohammad Yousefi,&nbsp;Atieh Pourbagheri-Sigaroodi,&nbsp;Zahra Fakhroueian,&nbsp;Sina Salari,&nbsp;Kosar Fateh,&nbsp;Majid Momeny,&nbsp;Davood Bashash","doi":"10.18502/ijhoscr.v16i3.10136","DOIUrl":"https://doi.org/10.18502/ijhoscr.v16i3.10136","url":null,"abstract":"<p><p><b>Background:</b> Therapeutic approaches for acute myeloid leukemia (AML) have remained largely unchanged for over 40 years and cytarabine and an anthracycline (e.g., daunorubicin) backbone is the main induction therapy for these patients. Resistance to chemotherapy is the major clinical challenge and contributes to short-term survival with a high rate of disease recurrence. Given the established efficacy of nanoparticles in cancer treatment, this study was designed to evaluate the anticancer property of our novel nanocomposite in the AML-derived KG1 cells. <b>Materials and Methods:</b> To assess the anti-leukemic effects of our nanocomposite on AML cells, we used MTT and trypan blue assays. Flow cytometric analysis and q-RT-PCR were also applied to evaluate the impact of nanocomposite on cell cycle and apoptosis. <b>Results:</b> Our results outlined that ZnO/CNT@Fe<sub>3</sub>O<sub>4</sub> decreased viability and metabolic activity of KG1 cells through induction of G1 arrest by increasing the expression of p21 and p27 cyclin-dependent kinase inhibitors and decreasing c-Myc transcription. Moreover, ZnO/CNT@Fe<sub>3</sub>O<sub>4</sub> markedly elevated the percentage of apoptotic cells which was coupled with a significant alteration of Bax and Bcl-2 expressions. Synergistic experiments showed that ZnO/CNT@Fe<sub>3</sub>O<sub>4</sub> enhances the cytotoxic effects of Vincristine on KG1 cells. <b>Conclusion:</b> In conclusion, this study sheds light on the potent anti-leukemic effects of ZnO/CNT@Fe<sub>3</sub>O<sub>4</sub> and provides evidence for the application of this agent in the treatment of acute myeloid leukemia.</p>","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"16 3","pages":"140-150"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/da/IJHOSCR-16-140.PMC9831873.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10671885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microbiota and Hematological Diseases. 微生物群与血液系统疾病。
International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2022-07-01 DOI: 10.18502/ijhoscr.v16i3.10139
Guido D'Angelo
{"title":"Microbiota and Hematological Diseases.","authors":"Guido D'Angelo","doi":"10.18502/ijhoscr.v16i3.10139","DOIUrl":"https://doi.org/10.18502/ijhoscr.v16i3.10139","url":null,"abstract":"<p><p>The microbiota is directly involved in the host metabolic process, as well as in immune response modulation and recruitment of different cells typology in the inflammatory site. Human microbiota modification (dysbiosis) is a condition which could be correlated with various pathologies. The short-chain fatty acids produced by the metabolic process have an important role as immune mediators. In hematology field, dysbiosis can represent a predisposing condition for triggering and/or conditioning both non-neoplastic (iron deficiency anemia, thrombosis, thrombocytosis or thrombocytopenia) and neoplastic disorders (lymphomas, leukemias, myeloma). Dysbiosis may also interfere on therapy efficacy (iron supplementation, chemotherapy, immunotherapy, and hematopoietic stem cell transplantation), impacting on patient's outcome.</p>","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"16 3","pages":"164-173"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a4/cf/IJHOSCR-16-164.PMC9831866.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10671891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Non-Invasive Liver Fibrosis Scores can Predict Hepatic Metastasis in Colorectal Cancers 无创肝纤维化评分可预测结直肠癌的肝转移
International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2022-04-30 DOI: 10.4999/uhod.225774
S. Karakaya
{"title":"Non-Invasive Liver Fibrosis Scores can Predict Hepatic Metastasis in Colorectal Cancers","authors":"S. Karakaya","doi":"10.4999/uhod.225774","DOIUrl":"https://doi.org/10.4999/uhod.225774","url":null,"abstract":"It was aimed to investigate the relationship between liver fibrosis and liver metastasis by using AST to Platelet Ratio Index (APRI) and Fibrosis4 (FIB4) non-invasive hepatic fibrosis scorings at the time of diagnosis in patients with nonmetastatic colorectal cancers (CRC) at diagnosis. A total of 1452 patients with colorectal cancer who were followed up between 2015-2020 were retrospectively reviewed. Seven hundred and fifty eight patients were included in the study. Fifty four patients who devoloped liver metastatis were compared with 704 patients who did not develop metastasis, the mean APRI score and mean FIB4 score at the time of diagnosis was determined to be significantly higher in the group with liver metastasis. The area under the curve (AUC) for the APRI score was 0.735 and the optimum sensitivity for detecting liver metastasis was 75.9%, while the optimal specificity was 65.1% and for the FIB4 score, AUC was 0.738, the optimum sensitivity for detecting liver metastasis was 74.1% and the specificity was 67.4%. When multivariate logistic regression analysis was conducted, FIB4 score, APRI score, Tstage, and Nstage were found as independent predictive factors in predicting liver metastasis It has been demonstrated that the group that may develop liver metastasis among patients with non-metastatic CRC at the time of diagnosis could be predicted by using the noninvasive liver fibrosis markers FIB4 and APRI scores. Moreover, it has been shown that these two scorings are also independent predictive markers. Based on this, shorter surveillance intervals may be an option in the group with higher FIB4 and APRI scores at the time of diagnosis.","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81459372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Data of Nivolumab and Pembrolizumab in Platinum Refractory Advanced Non-Small Cell Lung Cancer: Potential Practical Predictors of Treatment 纳武单抗和派姆单抗治疗铂难治性晚期非小细胞肺癌的实际数据:治疗的潜在实用预测因素
International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2022-04-30 DOI: 10.4999/uhod.226042
Omer Diker
{"title":"Real-World Data of Nivolumab and Pembrolizumab in Platinum Refractory Advanced Non-Small Cell Lung Cancer: Potential Practical Predictors of Treatment","authors":"Omer Diker","doi":"10.4999/uhod.226042","DOIUrl":"https://doi.org/10.4999/uhod.226042","url":null,"abstract":"","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88796513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Prognostic Significance of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase on the outcome of Adult Acute Myeloid Leukemia Patients with Cytarabine Based Chemotherapy 脱氧胞苷激酶和胞苷脱氨酶基因多态性对成人急性髓系白血病阿糖胞苷化疗预后的影响
International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2022-04-30 DOI: 10.4999/uhod.225940
Eman O Rasekh
{"title":"The Prognostic Significance of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase on the outcome of Adult Acute Myeloid Leukemia Patients with Cytarabine Based Chemotherapy","authors":"Eman O Rasekh","doi":"10.4999/uhod.225940","DOIUrl":"https://doi.org/10.4999/uhod.225940","url":null,"abstract":"Cytarabine (Ara-C) is the mainstay of treatment of acute myeloid leukemia (AML), but still, drug resistance and treatment-related toxicities are the main causes of treatment failure. Single nucleotide polymorphisms (SNPs) of the key genes involved in the metabolic pathway of Ara-C have been reported to affect the clinical outcome, so we aimed to investigate the potential association of SNPs of deoxycytidine kinase [DCK] 201C>T (rs2306744), DCK 360C>G (rs377182313) and cytidine deaminase (CDA) 79A>C (rs2072671) genes in adult Egyptian AML patients with the outcome. Genotyping of the studied SNPs was tested using PCR- RFLP technique in 142 adult de novo AML patients who received standard induction chemotherapy based on cytarabine and doxorubicin (3+7 protocol). The median (range) age of our patients was 38 (20-60) years. The studied SNPs genotypes had no significant influence on treatment response on day 28 of induction therapy. DCK 201 heterozygous CT genotype, DCK 201-T allele, [DCK 201(CC)/DCK 360(CC)/CDA 79(AC)] combination as well as hepatological, nephrological, neurological and hematological toxicities were independent prognostic markers on the survival of our AML patients. Nucleophosmin mutation was associated with the poor prognostic variant DCK 201-T and CDA 79-A alleles. Fms-like tyrosine3 kinase internal tandem duplication (FLT3-ITD) mutation was associated with the wild AA genotype of CDA 79A>C polymorphism, while FLT3-tyrosine kinase domain (TKD) mutation was associated with variant DCK360-G allele. These findings support the idea that the studied SNPs can be used as prognostic markers helping in tailored treatment for AML patients.","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"71 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83934063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Significance of Serum Human Epididymis Protein 4 Level in Patients with Locally Advanced Non-Small Cell Lung Cancer who Underwent Definitive Chemo-Radiotherapy 人附睾蛋白4水平在局部晚期非小细胞肺癌晚期化疗患者中的预后意义
International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2022-04-30 DOI: 10.4999/uhod.226025
G. Yavas
{"title":"Prognostic Significance of Serum Human Epididymis Protein 4 Level in Patients with Locally Advanced Non-Small Cell Lung Cancer who Underwent Definitive Chemo-Radiotherapy","authors":"G. Yavas","doi":"10.4999/uhod.226025","DOIUrl":"https://doi.org/10.4999/uhod.226025","url":null,"abstract":"","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85387312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of Mitochondrial DNA Gene Mutations in a Turkish Head and Neck Squamous Cancer Patient Group 土耳其头颈部鳞状癌患者组线粒体DNA基因突变的鉴定
International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2022-04-30 DOI: 10.4999/uhod.226394
P. Mutlu
{"title":"Identification of Mitochondrial DNA Gene Mutations in a Turkish Head and Neck Squamous Cancer Patient Group","authors":"P. Mutlu","doi":"10.4999/uhod.226394","DOIUrl":"https://doi.org/10.4999/uhod.226394","url":null,"abstract":"","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"80 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77562809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信